These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32145961)

  • 1. [Androgen receptor-positive triple negative breast cancer: From biology to therapy].
    Grellety T
    Bull Cancer; 2020 Apr; 107(4):506-516. PubMed ID: 32145961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Androgen receptors in breast cancer: Expression, value and therapeutic prospects].
    Héquet D; Mzoughi S; Rouzier R; Guccione E
    Bull Cancer; 2017 Apr; 104(4):363-369. PubMed ID: 28216075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revising the role of the androgen receptor in breast cancer.
    Fioretti FM; Sita-Lumsden A; Bevan CL; Brooke GN
    J Mol Endocrinol; 2014 Jun; 52(3):R257-65. PubMed ID: 24740738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
    Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
    Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
    Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
    Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
    Rhanine Y; Bonnefoi H; Goncalves A; Debled M; Le Moulec S; Bonichon N; Macgrogan G; Arnedos M; Dubroca-Dehez B; Grellety T
    Breast; 2024 Feb; 73():103667. PubMed ID: 38160476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Robles AJ; Cai S; Cichewicz RH; Mooberry SL
    Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the androgen receptor in prostate cancer.
    Culig Z
    Expert Opin Pharmacother; 2014 Jul; 15(10):1427-37. PubMed ID: 24890318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.
    Kim KP; Parise RA; Holleran JL; Lewis LD; Appleman L; van Erp N; Morris MJ; Beumer JH
    J Pharm Biomed Anal; 2017 May; 138():197-205. PubMed ID: 28219796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.
    Grellety T; Callens C; Richard E; Briaux A; Vélasco V; Pulido M; Gonçalves A; Gestraud P; MacGrogan G; Bonnefoi H; Cardinaud B
    Clin Cancer Res; 2019 Jan; 25(2):856-867. PubMed ID: 30352905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
    Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
    Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.